Rapamycin off-label use: evidence, risks, and decision boundaries

Rapamycin is one of the most discussed off-label longevity drugs and one of the easiest to misuse. Mechanistic promise is real, but human endpoint evidence is still limited and risk management is non-trivial. This guide covers what is known, unknown, and clinically non-negotiable.[5]

Rapamycin has mechanistic promise but limited definitive human longevity evidence.

Risk monitoring is mandatory for any off-label discussion.

Foundational risk markers should be optimized before considering advanced layers.